Get the Stockscreener App
17.29
1.65%
0.28
Keros Therapeutics Inc stock is traded at $17.29, with a volume of 501.14K.
It is up +1.65% in the last 24 hours and up +14.96% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$17.01
Open:
$17.02
24h Volume:
501.14K
Relative Volume:
0.60
Market Cap:
$527.06M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-3.3704
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
-1.48%
1M Performance:
+14.96%
6M Performance:
+18.67%
1Y Performance:
-69.44%
1-Day Range:
$16.88
$17.46
1-Week Range:
$16.31
$18.42
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
17.30 | 518.23M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.20 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.39 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.20 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.33 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
ExodusPoint Capital Management, LP's Strategic Acquisition of Keros Therapeutics Inc. Shares - GuruFocus
Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer - Latham & Watkins LLP
The Technical Signals Behind (KROS) That Institutions Follow - news.stocktradersdaily.com
Keros Therapeutics announces final results of tender offer - MarketScreener
[SC TO-I/A] Keros Therapeutics, Inc. Amended Issuer Tender Offer | KROS SEC FilingForm SC TO-I/A - Stock Titan
Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - The Manila Times
Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
How to manage a losing position in Keros Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
How to recover losses in Keros Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Is Keros Therapeutics Inc. stock attractive for income investors2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Will Keros Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Summary & Daily Chart Pattern Signals - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
Will Keros Therapeutics Inc. price bounce be sustainable2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Evaluating Keros Therapeutics Inc. with trendline analysisEntry Point & Short-Term Trading Opportunity Alerts - newser.com
Can volume confirm reversal in Keros Therapeutics Inc.July 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Will Keros Therapeutics Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat
Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq
Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating - MarketScreener
Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation - Nasdaq
KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig - GuruFocus
KROS vs. ARGX: Which Stock Is the Better Value Option? - MSN
Keros Therapeutics, Inc. : Wells Fargo Cuts T - 富途牛牛
Keros Therapeutics Drives Nasdaq Composite Momentum In Medicine - Kalkine Media
How interest rate cuts could boost Keros Therapeutics Inc. stockDay Trade & AI Enhanced Execution Alerts - newser.com
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '25 |
Sale |
17.75 |
5,389,264 |
95,659,436 |
0 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):